The latest earnings season has provided insights into the future of medtech in the COVID-19 landscape and what certain sectors are seeing as vaccines start to roll out.

Since the start of the pandemic, 113.1 million COVID-19 cases have been reported worldwide, according to Johns Hopkins University School of Medicine. The U.S. leads the world in infections, accounting for 28.4 million cases. More than 2.5 million people have died from the virus globally. Medtech has been on the frontlines throughout the pandemic, whether it was shifting production to make ventilators or PPE or developing COVID-19 tests and vaccines.

More than a year since the virus’ appearance in the U.S., some medtech CEOs are gaining a better understanding of how the industry may look moving forward. From stockpiling to new COVID-19 variants posing risks, here are the insights from seven CEOs.

Next >>